EAPI Stock Overview
Develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. More details
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Euroapi S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.81 |
52 Week High | €7.02 |
52 Week Low | €2.26 |
Beta | 0.53 |
1 Month Change | -20.22% |
3 Month Change | -30.38% |
1 Year Change | -49.91% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -79.21% |
Recent News & Updates
Recent updates
Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 25% Below Its Share Price
Oct 04There's No Escaping Euroapi S.A.'s (EPA:EAPI) Muted Revenues Despite A 32% Share Price Rise
Jul 29Euroapi S.A. (EPA:EAPI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 24Euroapi (EPA:EAPI) Seems To Be Using A Lot Of Debt
Apr 10Little Excitement Around Euroapi S.A.'s (EPA:EAPI) Revenues As Shares Take 31% Pounding
Mar 03Euroapi S.A. Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
Mar 02A Look At The Fair Value Of Euroapi S.A. (EPA:EAPI)
Dec 21Analysts Are Updating Their Euroapi S.A. (EPA:EAPI) Estimates After Its Half-Yearly Results
Aug 04Is Euroapi S.A. (EPA:EAPI) Trading At A 49% Discount?
Aug 02Euroapi S.A.'s (EPA:EAPI) Subdued P/S Might Signal An Opportunity
Jun 16An Intrinsic Calculation For Euroapi S.A. (EPA:EAPI) Suggests It's 37% Undervalued
Jan 25Euroapi S.A.'s (EPA:EAPI) Intrinsic Value Is Potentially 38% Above Its Share Price
Oct 15Statutory Profit Doesn't Reflect How Good Euroapi's (EPA:EAPI) Earnings Are
Sep 09Shareholder Returns
EAPI | FR Pharmaceuticals | FR Market | |
---|---|---|---|
7D | -5.5% | 2.0% | -1.7% |
1Y | -49.9% | 1.0% | -4.8% |
Return vs Industry: EAPI underperformed the French Pharmaceuticals industry which returned 1% over the past year.
Return vs Market: EAPI underperformed the French Market which returned -4.8% over the past year.
Price Volatility
EAPI volatility | |
---|---|
EAPI Average Weekly Movement | 10.0% |
Pharmaceuticals Industry Average Movement | 3.5% |
Market Average Movement | 4.5% |
10% most volatile stocks in FR Market | 9.7% |
10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: EAPI's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: EAPI's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 3,329 | Ludwig De Mot | www.euroapi.com/en |
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use. It provides contract development manufacturing organization for different classes of tides that uses solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; steroids and hormones; and opiates and controlled substances, as well as lipids. The company was incorporated in 2020 and is based in Paris, France.
Euroapi S.A. Fundamentals Summary
EAPI fundamental statistics | |
---|---|
Market cap | €267.69m |
Earnings (TTM) | -€287.30m |
Revenue (TTM) | €971.30m |
0.3x
P/S Ratio-0.9x
P/E RatioIs EAPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EAPI income statement (TTM) | |
---|---|
Revenue | €971.30m |
Cost of Revenue | €805.80m |
Gross Profit | €165.50m |
Other Expenses | €452.80m |
Earnings | -€287.30m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 11, 2025
Earnings per share (EPS) | -3.02 |
Gross Margin | 17.04% |
Net Profit Margin | -29.58% |
Debt/Equity Ratio | 50.9% |
How did EAPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 04:19 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Euroapi S.A. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Gary Steventon | BNP Paribas Exane |
Ben Spruntulis | BNP Paribas Exane |
Patrick Andrew Wood | BofA Global Research |